Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavel, Marianne, Gross, David J, Benavent, Marta, Perros, Petros, Srirajaskanthan, Raj, Warner, Richard R P, Kulke, Matthew H, Anthony, Lowell B, Kunz, Pamela L, Hörsch, Dieter, Weickert, Martin O, Lapuerta, Pablo, Jiang, Wenjun, Kassler-Taub, Kenneth, Wason, Suman, Fleming, Rosanna, Fleming, Douglas, Garcia-Carbonero, Rocio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811631/
https://www.ncbi.nlm.nih.gov/pubmed/29330194
http://dx.doi.org/10.1530/ERC-17-0455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811631/
https://www.ncbi.nlm.nih.gov/pubmed/29330194
http://dx.doi.org/10.1530/ERC-17-0455

Ejemplares similares